Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	**Mayne Pharma Group Limited**
ABN	**76 115 832 963**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Shawn Patrick O'Brien
Date of last notice	05 September 2024

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Solium Nominees (Australia) Pty Ltd as custodian for the Mayne Pharma Group Performance Rights and Option Plan (the '**Plan**')
Date of change	2 December 2024
No. of securities held prior to change	Direct: 630,841 Performance Rights Nil RSU Performance Rights 37,041 Ordinary Shares Indirect: 23,816 Ordinary Shares held by Solium Nominees (Australia) Pty Ltd as custodian for the Mayne Pharma Group Performance Rights and Option Plan (the '**Plan**')
Class	Performance Rights
Number acquired	301,455 Performance Rights 35,170 RSU Performance Rights

+ See chapter 19 for defined terms.

Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Performance Rights - Nil
No. of securities held after change	Direct: 932,296 Performance Rights 35,170 RSU Performance Rights 37,041 Ordinary Shares Indirect: 23,816 Ordinary Shares held by Solium Nominees (Australia) Pty Ltd as custodian for the Mayne Pharma Group Performance Rights and Option Plan (the '**Plan**')
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Performance Rights and RSU Performance Rights pursuant to Resolution 4 in the Notice of Meeting for the Company's 2024 Annual General Meeting.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

+ See chapter 19 for defined terms.